Finally, Ccnd1, Gpc3, Mvk, Pparg, Rbl2, and Robo1 exhibited a tumor-specific response (Figure 2C), where adverse expression changes were observed for Pparg, which appeared down regulated in transgenic cells (fold change <0.4) and significantly up regulated in tumors. This evidence concerns the gene RBL2 and neoplasm.